<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font6" size="10" family="SymbolMT" color="#000000"/>
	<fontspec id="font7" size="10" family="Giovanni,Bold" color="#000000"/>
<text top="41" left="55" width="192" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">World Journal of Emergency Surgery 2006, 1 :15<i>World Journal of Emergency Surgery</i></text>
<text top="41" left="417" width="137" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://www.wjes.org/content/1/1/15</text>
<text top="756" left="503" width="51" height="10" font="font1" id="p1_t3" reading_order_no="85" segment_no="35" tag_type="text">Page 9 of 11<b>1</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="86" segment_no="36" tag_type="text">(page number not for citation purposes)</text>
<text top="87" left="55" width="241" height="9" font="font4" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="text">tigated individual mediators or effectors, which limits the</text>
<text top="98" left="55" width="241" height="9" font="font4" id="p1_t6" reading_order_no="3" segment_no="2" tag_type="text">interpretation of effector function in the tissues. Further-</text>
<text top="110" left="55" width="241" height="9" font="font4" id="p1_t7" reading_order_no="4" segment_no="2" tag_type="text">more, cytokines often have crosstalk or cumulative effect<i>(page number not for citation purposes)</i></text>
<text top="122" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="5" segment_no="2" tag_type="text">and insight in the group effect of cytokines and chemok-</text>
<text top="134" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="6" segment_no="2" tag_type="text">ines would provide more accurate information about the</text>
<text top="145" left="55" width="41" height="9" font="font4" id="p1_t10" reading_order_no="7" segment_no="2" tag_type="text">net effect.</text>
<text top="169" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="8" segment_no="6" tag_type="text">The scoring systems ought to be used to define the appro-</text>
<text top="181" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="9" segment_no="6" tag_type="text">priate therapy. Damage control surgery and damage con-</text>
<text top="192" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="10" segment_no="6" tag_type="text">trol orthopedics are currently used strategies to limit the</text>
<text top="204" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="11" segment_no="6" tag_type="text">incidence of organ failure after trauma [76,77]. Timing of</text>
<text top="216" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="6" tag_type="text">surgery is essential in this damage control approach and</text>
<text top="228" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="13" segment_no="6" tag_type="text">recent literature provides a timeframe for planning inter-</text>
<text top="239" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="14" segment_no="6" tag_type="text">ventions [78,79]. This timeframe, which is based on data-<a href="">ma [76</a>,<a href="">77]. Tim</a>ing of</text>
<text top="251" left="55" width="241" height="9" font="font4" id="p1_t18" reading_order_no="15" segment_no="6" tag_type="text">base analysis, is not fully complementary with the</text>
<text top="263" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="16" segment_no="6" tag_type="text">activation status of the innate immune system. According</text>
<text top="275" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="17" segment_no="6" tag_type="text">to the measurements of neutrophils (oxidative burst and<a href="">ntions [78,79</a>]. This timeframe, which is based on data-</text>
<text top="286" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="18" segment_no="6" tag_type="text">L-selectin) hyper-inflammation is at its maximum 6 hours</text>
<text top="298" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="19" segment_no="6" tag_type="text">after trauma, whereas according to the damage control</text>
<text top="310" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="20" segment_no="6" tag_type="text">timeframe hyper-inflammation is present between day 2â€“</text>
<text top="322" left="55" width="241" height="9" font="font4" id="p1_t24" reading_order_no="21" segment_no="6" tag_type="text">4 [20,26]. Despite this problem in defining the timeframe,</text>
<text top="333" left="55" width="241" height="9" font="font4" id="p1_t25" reading_order_no="22" segment_no="6" tag_type="text">solutions are sought to prevent the excessive inflamma-</text>
<text top="345" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="23" segment_no="6" tag_type="text">tion. A recent therapy that became available, hemoglobin</text>
<text top="357" left="55" width="241" height="9" font="font4" id="p1_t27" reading_order_no="24" segment_no="6" tag_type="text">based oxygen carriers as alternative for packed red blood<a href="">[20,26</a>]. Despite this problem in defining the timeframe,</text>
<text top="369" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="25" segment_no="6" tag_type="text">cells, show promising results in limiting the inflammatory</text>
<text top="380" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="6" tag_type="text">response [28]. The start of hypo-inflammation is less well</text>
<text top="392" left="55" width="241" height="9" font="font4" id="p1_t30" reading_order_no="27" segment_no="6" tag_type="text">defined and more individual determined, which makes</text>
<text top="404" left="55" width="95" height="9" font="font4" id="p1_t31" reading_order_no="28" segment_no="6" tag_type="text">therapy more difficult.</text>
<text top="428" left="55" width="56" height="10" font="font5" id="p1_t32" reading_order_no="29" segment_no="19" tag_type="title">Conclusion<a href="">[28]. Th</a>e start of hypo-inflammation is less well</text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t33" reading_order_no="30" segment_no="20" tag_type="text">Several studies have shown a relationship between the</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t34" reading_order_no="31" segment_no="20" tag_type="text">severity of trauma and the resulting immune response</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t35" reading_order_no="32" segment_no="20" tag_type="text">[75]. The injury to the host can be expressed in scoring<b>Conclusion</b></text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t36" reading_order_no="33" segment_no="20" tag_type="text">systems and these have become important prognostic</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="20" tag_type="text">tools to calculate the risk based on clinical signs and</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t38" reading_order_no="35" segment_no="20" tag_type="text">symptoms in combination with inflammatory parameters<a href="">[75]. Th</a>e injury to the host can be expressed in scoring</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t39" reading_order_no="36" segment_no="20" tag_type="text">[68]. It is likely that a threshold needs to be reached before</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="20" tag_type="text">clinical symptoms become evident. The loss of barrier</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="20" tag_type="text">integrity of different organs seems to play a major role in</text>
<text top="545" left="55" width="241" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="20" tag_type="text">the development of complications in both the pro-inflam-<a href="">[68]. It is likely that</a> a threshold needs to be reached before</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t43" reading_order_no="40" segment_no="20" tag_type="text">matory period and the anti-inflammatory period. Studies</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t44" reading_order_no="41" segment_no="20" tag_type="text">which focus on the interaction between host and innate</text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t45" reading_order_no="42" segment_no="20" tag_type="text">immunity are to be performed to resolve the post-trau-</text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="20" tag_type="text">matic complications resulting in organ failure. Immuno-</text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t47" reading_order_no="44" segment_no="20" tag_type="text">monitoring with interpretation of group effects of</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t48" reading_order_no="45" segment_no="20" tag_type="text">cytokines or analysis of effector cells in interaction with</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="20" tag_type="text">tissue may lead to more intensive immunomonitoring</text>
<text top="639" left="55" width="241" height="9" font="font4" id="p1_t50" reading_order_no="47" segment_no="20" tag_type="text">and the adjustment of therapeutic and supportive strate-</text>
<text top="651" left="55" width="228" height="9" font="font4" id="p1_t51" reading_order_no="48" segment_no="20" tag_type="text">gies for the optimalization of care for trauma-patients.</text>
<text top="674" left="55" width="70" height="10" font="font5" id="p1_t52" reading_order_no="49" segment_no="30" tag_type="title">Abbreviations</text>
<text top="686" left="55" width="179" height="9" font="font4" id="p1_t53" reading_order_no="50" segment_no="31" tag_type="text">ARDS: Acute respiratory distress syndrome</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t54" reading_order_no="51" segment_no="33" tag_type="text">CARS: Compensatory anti-inflammatory response syn-</text>
<text top="721" left="55" width="28" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="33" tag_type="text">drome<b>Abbreviations</b></text>
<text top="87" left="313" width="101" height="9" font="font4" id="p1_t56" reading_order_no="53" segment_no="3" tag_type="text">CRP: C-Reactive protein</text>
<text top="110" left="313" width="241" height="9" font="font4" id="p1_t57" reading_order_no="54" segment_no="4" tag_type="text">GM-CSF: Granulocyte macrophage colony stimulating</text>
<text top="122" left="313" width="24" height="9" font="font4" id="p1_t58" reading_order_no="55" segment_no="4" tag_type="text">factor</text>
<text top="145" left="313" width="156" height="9" font="font4" id="p1_t59" reading_order_no="56" segment_no="5" tag_type="text">HMGB-1: High mobility group box 1</text>
<text top="169" left="313" width="180" height="9" font="font4" id="p1_t60" reading_order_no="57" segment_no="7" tag_type="text">ICAM-1: Intercellular adhesion molecule 1</text>
<text top="192" left="313" width="78" height="9" font="font4" id="p1_t61" reading_order_no="58" segment_no="8" tag_type="text">IL-n: Interleukin-n</text>
<text top="216" left="313" width="104" height="9" font="font4" id="p1_t62" reading_order_no="59" segment_no="9" tag_type="text">ISS: Injury Severity Score</text>
<text top="239" left="313" width="95" height="9" font="font4" id="p1_t63" reading_order_no="60" segment_no="10" tag_type="text">MAC-1: Macrophage 1</text>
<text top="263" left="313" width="187" height="9" font="font4" id="p1_t64" reading_order_no="61" segment_no="11" tag_type="text">MARS: Mixed antagonist response syndrome</text>
<text top="286" left="313" width="190" height="9" font="font4" id="p1_t65" reading_order_no="62" segment_no="12" tag_type="text">MHC-II: Major histocompatibility complex II</text>
<text top="310" left="313" width="189" height="9" font="font4" id="p1_t66" reading_order_no="63" segment_no="13" tag_type="text">MIF: Macrophage migration inhibitory factor</text>
<text top="333" left="313" width="194" height="9" font="font4" id="p1_t67" reading_order_no="64" segment_no="14" tag_type="text">MODS: Multiple organ dysfunction syndrome</text>
<text top="357" left="313" width="119" height="9" font="font4" id="p1_t68" reading_order_no="65" segment_no="15" tag_type="text">MOF: Multiple organ failure</text>
<text top="380" left="313" width="119" height="9" font="font4" id="p1_t69" reading_order_no="66" segment_no="16" tag_type="text">ROS: Radical oxygen species</text>
<text top="404" left="313" width="93" height="9" font="font4" id="p1_t70" reading_order_no="67" segment_no="17" tag_type="text">sICAM: Soluble ICAM</text>
<text top="427" left="313" width="205" height="9" font="font4" id="p1_t71" reading_order_no="68" segment_no="18" tag_type="text">SIRS: Systemic inflammatory response syndrome</text>
<text top="451" left="313" width="110" height="9" font="font4" id="p1_t72" reading_order_no="69" segment_no="21" tag_type="text">TGF: Tumor growth factor</text>
<text top="471" left="313" width="132" height="12" font="font4" id="p1_t73" reading_order_no="70" segment_no="22" tag_type="text">TNF- Î± : Tumor necrosis factor Î±</text>
<text top="498" left="313" width="103" height="10" font="font5" id="p1_t74" reading_order_no="71" segment_no="23" tag_type="title">Competing interests</text>
<text top="510" left="313" width="241" height="9" font="font4" id="p1_t75" reading_order_no="72" segment_no="24" tag_type="text">The author(s) declare that they have no competing inter-</text>
<text top="521" left="313" width="18" height="9" font="font4" id="p1_t76" reading_order_no="73" segment_no="24" tag_type="text">ests.</text>
<text top="545" left="313" width="114" height="10" font="font5" id="p1_t77" reading_order_no="74" segment_no="25" tag_type="title">Authors' contributions</text>
<text top="557" left="313" width="241" height="9" font="font7" id="p1_t78" reading_order_no="75" segment_no="26" tag_type="text">FH participated in the design of the review and drafted the</text>
<text top="568" left="313" width="50" height="9" font="font4" id="p1_t79" reading_order_no="76" segment_no="26" tag_type="text">manuscript.</text>
<text top="592" left="313" width="241" height="9" font="font7" id="p1_t80" reading_order_no="77" segment_no="27" tag_type="text">LK revised the manuscript critically on the content of<b>Competing interests</b></text>
<text top="604" left="313" width="214" height="9" font="font4" id="p1_t81" reading_order_no="78" segment_no="27" tag_type="text">effector processes till the final version was reached.</text>
<text top="627" left="313" width="241" height="9" font="font7" id="p1_t82" reading_order_no="79" segment_no="28" tag_type="text">GR revised the manuscript critically on the mediator proc-</text>
<text top="639" left="313" width="161" height="9" font="font4" id="p1_t83" reading_order_no="80" segment_no="28" tag_type="text">esses till the final version was reached.<b>Authors' contributions</b></text>
<text top="662" left="313" width="241" height="9" font="font7" id="p1_t84" reading_order_no="81" segment_no="29" tag_type="text">LL participated in the design of the review and revised the<b>FH </b></text>
<text top="674" left="313" width="189" height="9" font="font4" id="p1_t85" reading_order_no="82" segment_no="29" tag_type="text">manuscript till the final version was reached.</text>
<text top="698" left="313" width="241" height="9" font="font4" id="p1_t86" reading_order_no="83" segment_no="32" tag_type="text">The authors have read and approved the final manuscript.</text>
<text top="721" left="313" width="99" height="10" font="font5" id="p1_t87" reading_order_no="84" segment_no="34" tag_type="title">Acknowledgements<b>LK </b></text>
</page>
</pdf2xml>
